Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut plus )

被引：1
|
作者：
Petruzelka, Lubos [1 ,2 ]
机构：
[1] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic
[2] Charles Univ Prague, Fac Med 1, Inst Radiat Oncol, Prague, Czech Republic
来源：
LUNG CANCER | 2012年 / 77卷
关键词：
D O I：
10.1016/j.lungcan.2012.05.042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [1] Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Kim, Young Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 692 - +
  • [2] Erlotinib A Guide to Its Use in First-Line Treatment of Non-Small-Cell Lung Cancer with Epidermal Growth Factor-Activating Mutations
    Lyseng-Williamson, Katherine A.
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2013, 17 (01) : 57 - 62
  • [3] First-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, Bartomeu
    Reguart, Noemi
    Vivanco, Guillermo Lopez
    Provencio, Mariano
    Isla, Dolores
    Camps, Carlos
    Ares, Luis Paz
    Pradas, Anna
    Taron, Miquel
    Rosell, Rafael
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 216 - 216
  • [4] Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and response to first-line erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Reguart-Aransay, Noemi
    Mayo, Clara
    Queralt, Cristina
    Botia, Monica
    Pastor, Carmen
    Perez, Maria
    Catot, Silvia
    Prada, Anna
    Galvez, Marc
    Taron, Miquel
    Rosell, Rafael
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [5] First-line erlotinib in stage IV non-small cell lung cancer (NSCLC) patients (pts) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, B.
    Porta, R.
    Paz-Ares, L.
    Cardenal, F.
    Lopez-Vivanco, G.
    Provencio, M.
    Isla, D.
    Pradas, A.
    Taron, M.
    Rosell, R.
    [J]. LUNG CANCER, 2006, 52 : S25 - S26
  • [6] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Merimsky, O.
    Cheng, A. C.
    Reck, M.
    Au, S. K.
    von Pawel, J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
  • [7] Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Zwitter, Matjaz
    Rajer, Mirjana
    Stanic, Karmen
    Vrankar, Martina
    Doma, Andrej
    Cuderman, Anka
    Grmek, Marko
    Kern, Izidor
    Kovac, Viljem
    [J]. CANCER BIOLOGY & THERAPY, 2016, 17 (08) : 833 - 839
  • [8] Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
    Cardenal, Felipe
    Moran, Teresa
    Queralt, Cristina
    Porta, Ruth
    Camps, Carlos
    Majem, Margarita
    Lopez-Vivanco, Guillermo
    Isla, Dolores
    Provencio, Mariano
    Sanchez, Jose Javier
    Taron, Miquel
    Rosell, Rafael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S324 - S325
  • [9] Response to first-line chemotherapy and sensitivity to epidermal growth factor receptor (EGFR) inhibitors in advanced non-small-cell lung cancer (NSCLC) patients
    Betti, Maura
    Toschi, L.
    Metro, G.
    Bartolini, Stefania
    Magrini, E.
    de Angelis, Verena
    Chiari, Rita
    Ferraldeschi, Massimiliano
    Cappuzzo, Federico
    Crino, Lucio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [10] Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
    Porta, R.
    Queralt, C.
    Cardenal, F.
    Mayo, C.
    Provencio, M.
    Camps, C.
    Isla, D.
    Gonzalez-Larriba, J.
    Taron, M.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345